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Edited by Varda RotterAbstract The ARF transcript produces two proteins, the full-
length ARF, p19ARF, and a short mitochondrial version, smARF.
To explore the functional diﬀerence between the two, we gener-
ated GFP-fused expression vectors for each protein and intro-
duced them into NIH3T3 murine ﬁbroblasts, which sustains a
global deletion in the INK4a locus but contains a functional
p53 gene. GFP-p19ARF was located within the nucleolus as pre-
viously reported, whereas GFP-smARF was detected mainly in
the nucleoplasm. GFP-smARF induced cell death although to a
slightly lesser extent than p19ARF. GFP-smARF stabilized p53
thereby inducing expression of the target genes, MDM2 and
p21. We suggest that smARF has functions other than mitochon-
dria-mediated autophagy, and induces p53 expression and cell
death via a novel mechanism.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: smARF; p53; Nuclear localization; MDM21. Introduction
The tumor suppressor gene locus INK4a encodes two diﬀer-
ent proteins, p16INK4a and ARF [1]. p16INK4a functions as a
Cdk inhibitor, binding to and inhibiting the activity of cyclin
D-dependent kinases, Cdk4 and Cdk6, thereby regulating the
action of the tumor suppressor, a retinoblastoma (pRb) protein
[2]. ARF (p19ARF and p14ARF for the mouse and human pro-
teins, respectively), on the other hand, negatively regulates the
activity of the ubiquitin ligaseMDM2 and inhibits the degrada-
tion of another tumor suppressor, p53 [3]. Therefore, the INK4a
locus plays a critical role in tumor suppression by regulating the
two major tumor suppressor proteins, pRb and p53. Consistent
with this idea, the INK4a locus is, in fact, frequently deleted or
epigenetically suppressed in a variety of human cancers [4,5].
In addition to the regulation of the MDM2-p53 pathway,
ARF is suggested to play a role in cell proliferation control
in a p53-independent manner [6]. For example, ARF is still
capable of inhibiting the proliferation of p53/MDM2/
cells although somewhat less eﬀectively than in wild-type con-
trol cells. ARF/p53/MDM2/ mice develop tumors at a
frequency slightly but deﬁnitely higher than that of
p53/MDM2/ animals [7]. Therefore, it is evident that*Corresponding author. Fax: +81 743 72 5519.
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doi:10.1016/j.febslet.2008.03.032ARF can control cell proliferation in a p53-independent man-
ner as well. Although the precise pathway has yet to be clari-
ﬁed, several possible mechanisms have been suggested. ARF
regulates ribosome biosynthesis [8] partially by binding to
and regulating nucleophosmin (NPM) [9–11]. ARF regulates
the activity of several transcription factors including myc by
direct binding [12]. Besides MDM2, ARF binds to and regu-
lates the activity of another ubiquitin ligase, ARF-BP1 or
Mule [13], which triggers degradation of several target proteins
including myc besides p53, some of which may be responsible
for p53-independent cell proliferation. Furthermore, it is re-
ported that the ARF transcript produces a shorter version of
the protein in addition to the full-length p19ARF polypeptide,
which starts from the internal methionine Met at position 45
and predominantly distributes in the mitochondria: this trun-
cated form has been designated short mitochondrial ARF
(smARF) [14]. smARF lacks the MDM2-binding domain lo-
cated in the N-terminus, and is suggested to play a role in
autophagy in a p53-independent manner. In this study, we ex-
plored the intracellular function of smARF to control cell pro-
liferation. We fused smARF with GFP, introduced it into
NIH3T3 cells, which sustain a wide range of deletions at the
INK4a gene locus, but contain a wild-type allele of p53 gene,
and examined its intracellular sublocalization and the eﬀect on
cell proliferation and survival.2. Materials and methods
2.1. Cell culture and transfection
NIH3T3 (Arf-null, p53-wild-type) mouse ﬁbroblasts, 293T human
embryonic kidney cells, and HeLa human cervical carcinoma cells were
cultured in Dulbeccos modiﬁed Eagles medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/
ml of penicillin, and 100 lg/ml of streptomycin (GIBCO/BRL), and
transfected with expression vectors via the calcium phosphate-DNA
precipitation method [15].
2.2. Plasmid construction
We constructed a GFP-fusion protein expression vector (pMSCV-
puro-GFP) [16] by modifying the retroviral vector pMSCV-IRES-puro
(Clontech). cDNA fragments containing the coding sequence of
smARF (Cdkn2a, smARF variant, GenBank accession number
EU071702) and the full-length p19ARF (Cdkn2a, variant 1,
p19ARF, GenBank accession number NM009877) were subcloned
into the pMSCV-puro-GFP vector in-frame with GFP.
2.3. Protein analyses
Cell lysis, immunoprecipitation, sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS–PAGE), and immunoblotting were per-
formed as described [16,17]. In short, cells were washed with PBS and
lysed for 30 min on ice in modiﬁed EBC buﬀer (50 mM Tris–HCl, pHblished by Elsevier B.V. All rights reserved.
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2000 KIU/ml of aprotinin, 1 mM PMSF, 0.1 mM NaF, 0.1 mM
Na3VO4, and 10 mM b-glycerophosphate. The cell debris was removed
by micro centrifugation at full speed. The antibodies were reacted with
cell lysates for 2 h to overnight at 4 C. Immune complexes were col-
lected by incubation with protein A or protein G Sepharose beads for
2 h at 4 C, and boiled in SDS-sample buﬀer (40 mM Tris–HCl, pH
6.8, 0.1 M DTT, 1% SDS, 10% glycerol, and 0.05% bromophenol blue)
for 4 min. To prepare direct lysates for immunoblotting, cell lysates in a
EBC buﬀer were mixed with the same amount of 2· SDS-sample buﬀer
(80 mM Tris–HCl, pH 6.8, 0.2 M DTT, 2% SDS, 20% glycerol, and
0.1% bromophenol blue) and boiled for 4 min. Protein samples were
separated on SDS–polyacrylamide gels under reducing conditions
(SDS–PAGE), transferred to a nitrocellulose membrane or a PVDF
membrane (Millipore), and immunoblotted with the antibodies indi-
cated. Proteins were detected with the ECL blotting system (Amer-
sham) according to the manufacturers instructions. Developed ﬁlms
were quantitatively analyzed with a densitograph (ATTO, Japan).
Rabbit polyclonal antibodies to p53 (FL-393) and Grb2 (C-23) and
a goat polyclonal antibody to p21 (C-19) were purchased from Santa
Cruz Biotechnology. A mouse monoclonal antibody to c-tubulin
(GTU-88) and a rabbit polyclonal antibody to p19ARF(Ab80) were
obtained from Sigma and Abcam, respectively. Rabbit polyclonal
antibodies to p53 and p21 were generated using bacterially produced
polypeptides in our laboratory. A mouse monoclonal antibody to
MDM2 was provided by Dr. Arnold J. Levine. Rabbit polyclonal anti-
body to GFP (BD Living Colors) was from BD Biosciences. Mouse
monoclonal antibody to an HA epitope (clone 12CA5) was purchased
from Boehringer Mannheim.
2.4. Immunoﬂuorescence staining
For the analysis of the subcellular localization of GFP-fused pro-
teins, NIH3T3, 293T, and HeLa cells were photographed by ﬂuores-
cence (GFP) microscopy (Olympus, Japan) at 48–72 h after
transfection. For the immunoﬂuorescence staining, cells were grown
on glass slides, ﬁxed in 4% paraformaldehyde, permeabilized in 0.5%
Triton X-100, stained with cell culture supernatant containing the
mouse monoclonal antibody indicated and incubated with ﬂuores-
cein-linked anti-mouse IgG (Amersham). Chromosomal DNA was
stained by incubation in 1 lg/ml of Hoechst 33342 for 2 min. The sam-
ples were viewed by phase-contrast or ﬂuorescence microscopy.
2.5. Flow cytometric analysis
For the cell cycle analysis, cells were stained with a 1 ml solution of
0.1% sodium citrate and 0.1% Triton X-100 containing 50 lg/ml of
propidium iodide and treated with 1 lg/ml of RNase for 30 min at
room temperature. Fluorescence from the propidium iodide–DNA
complex was measured with a FACScan ﬂow cytometer (Becton Dick-
inson), and the percentage of cells in the sub-G1 population was deter-
mined with Modiﬁt cell cycle software. The populations of dead cells
were conﬁrmed by the dye exclusion assay.
2.6. Cell fractionation
To perform the nuclear-enriched fractionation, cells were suspended
on ice in 0.1% NP40 buﬀer (10 mM HEPES–KOH, pH 7.8, 10 mM
KCl, 0.1 mM EDTA, and 0.1% NP40) supplemented with 0.1 mM
Na3VO4, 0.1 mM NaF, 10 mM b-glycerophosphate, 2% aprotinin,
and 0.5% PMSF, homogenized by multiple passages through a 27 G
needle, incubated for 5 min on ice, and centrifuged at 2000 · g for
2 min at 4 C to pellet the nuclear fraction. The supernatant was recov-
ered as a cytoplasmic fraction (designated as N/C because this fraction
contained some nuclear fraction). The pelleted nuclear fraction was
extracted by homogenizing 10 passages through a 27 G needle in mod-
iﬁed EBC buﬀer supplemented with inhibitors, incubated for 1 h on ice,
and centrifuged at 18000 · g for 10 min at 4 C. The resulting superna-
tant was collected as a ﬁnal nuclear fraction (designated as N). Direct
lysate as described above was used as the whole cell fraction (W).3. Results
To visualize the intracellular behavior of the smARF pro-
tein, we constructed a vector that expresses the GFP-fusedsmARF protein. We subcloned smARF cDNA in-frame with
green ﬂuorescent protein (GFP) into the mammalian expres-
sion vector, pMSCV-puro-GFP [16], which expresses inserted
cDNA as the GFP-fusion protein under the control of the
MSCV promoter and contains the puromycin resistance gene
as a selection marker. As a control, we introduced full-length
p19ARF cDNA into the same vector in place of smARF cDNA.
The mouse ﬁbroblast cell line, NIH3T3, was used for the fol-
lowing analysis because this cell line contains a global deletion
in the INK4a locus and expresses neither p16INK4a nor p19ARF
(not smARF neither). But these cells retain the normal allele of
the p53 gene and in response to UV, c-ray, and DNA-damag-
ing reagents (alkylating chemicals), activation of p53 swiftly
occurs resulting in the induction of downstream target genes
such as p21 and MDM2 (data not shown but see [16]).
NIH3T3 cells were transfected with the expression vectors
(pMSCV-puro-GFP-smARF, pMSCV-puro-GFP-p19ARF,
and an empty vector, pMSCV-puro-GFP) by the calcium
phosphate precipitation technique [15]. The cells were har-
vested at 48 h post transfection, and the cell lysates were ana-
lyzed by Western blotting with the speciﬁc antibodies indicated
(Fig. 1A). An antibody to GFP readily recognized GFP and
GFP-fused proteins (GFP-p19ARF and GFP-smARF). The
antibody speciﬁc to the C-terminus of mouse ARF detected
GFP-fusion proteins of the same molecular weight. Impor-
tantly, neither antibody detected any species with a smaller
molecular weight, indicating that degradation of the ectopi-
cally expressed protein was under the detectable level, and
the GFP-signal is from the full-length fusion protein and not
from the truncated protein. In the lysate from the GFP-
p19ARF-transfected cells, we did not detect the polypeptide
with the lower molecular weight (ca 14 kDa, corresponding
to smARF) using the antibody recognizing both p19ARF and
smARF. It is likely that smARF protein is not produced from
the GFP-p19ARF transcript.
To explore the intracellular behavior of the smARF protein,
we examined NIH3T3 cells transfected with the GFP vectors
(pMSCV-puro-GFP-smARF, pMSCV-puro-GFP-p19ARF,
and an empty vector, pMSCV-puro-GFP) under the ﬂuores-
cent microscope (Fig. 2A). The GFP signal in pMSCV-puro-
GFP-transfected cells was observed throughout cell but was
slightly stronger in the nucleus, showing no sign of speciﬁc
intracellular localization, while the GFP signal in pMSCV-
puro-GFP-p19ARF-transfected cells was compartmentalized
within the nucleolus, consistent with the report that p19ARF
is located in the nucleolus. The GFP signal in pMSCV-puro-
GFP-smARF-transfected cells was, however, unexpectedly
detected mostly in the nucleus, some being in the cytoplasm,
but did not speciﬁcally localize within the mitochondria. Be-
cause Western blotting data conﬁrmed that there is little deg-
radation product (Fig. 1A), the GFP signal we observed
most probably reﬂects that of GFP-smARF. After counting
the cells with diﬀerent intracellular localization of the GFP sig-
nal, the results clearly showed that GFP-smARF mostly re-
sided in the nucleoplasm but was occasionally found in the
nucleolus as well (Fig. 2B), a clear distinction from the distri-
bution of the full-length p19ARF.
Because the nuclear localization of the GFP-smARF protein
was unexpected, we investigated whether this is speciﬁc to
mouse ﬁbroblasts. We transfected the cell lines, human embry-
onic kidney-derived HEK293T cells and human cervical carci-
noma-derived HeLa cells with the same set of vectors
Fig. 1. Expression of GFP-tagged p19ARF and smARF and sub-
cellular localization of smARF. (A) NIH3T3 cells were mock-
transfected (Mock) or transfected with vectors encoding GFP,
GFP-tagged p19ARF (GFP-p19ARF), and GFP-tagged smARF (GFP-
smARF). Cells were harvested at 48 h post-transfection and the lysates
were subjected to immunoblotting with antibodies speciﬁcally recog-
nizing C-terminus ARF (Left panel, ap19ARF) and GFP (aGFP). The
positions of GFP-p19ARF, GFP-smARF, and GFP are shown at the
right of the panels. The positions of the molecular weight markers are
indicated at the left of the panels. (B) NIH3T3 cells were transfected
with vectors encoding GFP-smARF and HA-smARF. Cells were
harvested at 48 h post-transfection and extracted to yield the nuclear
fraction (N) and the fraction containing both nuclei and cytoplasm
(N/C). The lysates (20 lg) were subjected to immunoblotting with
antibodies speciﬁcally recognizing nucleophosmin (NPM, marker
for nuclear protein), Grb2 (marker for cytoplasmic protein), and
C-terminus ARF. The position of each protein is shown at the right of
the panel. W: whole cell lysate (ca 60% of N and N/C fractions were
loaded in the lane).
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and an empty vector, pMSCV-puro-GFP) and examined the
subcellular localization of the GFP signal (Fig. 2C, and data
not shown). Again we found GFP-smARF largely in the
nucleus. Thus, we conclude that smARF harbors nuclear
transport potential.
smARF was reported to be transported into the mitochon-
dria and induce cell death by autophagy [14]. Since we found
GFP-smARF mainly in the nucleus, we investigated the eﬀect
of exogenously expressed GFP-smARF on the survival of
ARF-null NIH3T3 mouse ﬁbroblasts. NIH3T3 cells were
transfected with the expression vectors (pMSCV-puro-GFP-
smARF, pMSCV-puro-GFP-p19ARF, and an empty vector,
pMSCV-puro-GFP) and selected in medium containing puro-
mycin. Under these conditions, numerous colonies appeared in
the GFP vector-transfected culture, but few colonies grew in
the cultures transfected with GFP-smARF and GFP-p19ARF.
To determine whether this is due to loss of cell viability, weanalyzed cell viability by FACS at 48 h post-transfection with-
out selection in puromycin. To attempt to analyze the possibly
early event after expression of the transduced gene rather than
the late event, we harvested cells as early as 48 h post-transfec-
tion. Fig. 3 shows that transfection of GFP-p19ARF vector
resulted in cell death after 48 h. The frequency of cell death
was even higher later during the culture. The introduction of
GFP-smARF also induced cell death at this time point
although slightly less eﬃciently than that of GFP-p19ARF.
Similar results were obtained in the trypan blue dye exclusion
assay and when we used HA-tagged constructs. Given that the
protein expression was stronger for GFP-smARF than GFP-
p19ARF, full-length p19ARF induces cell death more eﬃciently.
However, the results clearly show that nuclear smARF is capa-
ble of inducing cell death.
p19ARF is known to activate p53 by directly binding to and
inhibiting the ubiquitin ligase MDM2 [18,19], whereas smARF
is reported not to do so [14]. Because we found GFP-smARF
in the nucleus, we examined whether the expression of GFP-
smARF has any impact on the MDM2-p53 pathway. NIH3T3
cells were transfected with the expression vectors (pMSCV-
puro-GFP-smARF, pMSCV-puro-GFP-p19ARF, and an
empty vector, pMSCV-puro-GFP) and harvested after 48 h.
Cell lysates were analyzed by Western blotting with antibodies
speciﬁc to p53, p21, and MDM2 (Fig. 4A). Transfection of
GFP-p19ARF activated p53 by increasing the level of p53,
thereby inducing the expression of downstream target genes
such as p21 and MDM2. Surprisingly, we observed an increase
of p53 expression in cells transfected with GFP-smARF. The
p53 appeared to be active because the downstream targets
p21 and MDM2 were also activated.
In order to examine the nuclear localization of GFP-smARF
by a diﬀerent approach, we performed cell fractionation exper-
iments. In a previously reported experiment, the nuclear frac-
tion was contaminated by a certain amount of the
cytoplasmic fraction [14], which prevented the obtaining of a
clear conclusion. We obtained two fractions: (1) a nuclear frac-
tion (designated as N) that exclusively contained extracts from
nuclei and (2) the nuclear/cytoplasmic fraction (designated as
N/C) that contained both nuclear and cytoplasmic fractions.
Each fraction was analyzed by Western blotting with antibod-
ies speciﬁcally recognizing nuclear protein (nucleophosmin,
NPM), cytoplasmic protein (Grb2), and the C-terminal por-
tion of ARF protein (therefore, recognizing both full-length
p19ARF and smARF). We also used the expression vector for
HA-tagged smARF to reduce the size-eﬀect of tagging.
Fig. 1B shows that the nuclear fraction (N) was pure enough
to be free from the cytoplasm because we did not detect any
Grb2 protein. GFP-smARF was detected in both the N and
N/C fractions, consistent with the results obtained by ﬂuores-
cent microscopy. As expected, we detected HA-tagged smARF
protein in both the N and N/C fractions, indicating that
regardless of the diﬀerent tags, smARF is capable of locating
in the nucleus as well as in the cytoplasm.
Because we found a fraction of smARF in the nucleus, we
decided to examine whether smARF and MDM2 may form a
stable complex in the cell by performing immunoprecipitation
followed by Western blotting. Because our antibody to GFP
is not well suited for immunoprecipitation, we decided to use
an antibody to the HA tag. NIH3T3 cells were transfected with
expression vectors for HA-p19ARF and HA-smARF, harvested
after 48 h, and immunoprecipitated with a mouse monoclonal
Fig. 2. Subcellular localization of the GFP-tagged proteins in mouse ﬁbroblasts and human cells. (A) NIH3T3 cells were transfected with vectors
encoding GFP, GFP-p19ARF, and GFP-smARF, and were examined under the ﬂuorescence microscope at 48 h post-transfection. PC: phase
contrast. (B) More than 500 cells transfected with vectors encoding GFP, GFP-p19ARF, and GFP-smARF were examined and enumerated under the
ﬂuorescence microscope at 48 h post-transfection. Data are shown as the percentage of the number of cells exhibiting diﬀerent localization of the
GFP signal. (C) HEK293T cells were transfected with vectors encoding GFP, GFP-p19ARF, and GFP-smARF, and were examined under the
ﬂuorescence microscope at 48 h post-transfection. PC: phase contrast.
Fig. 4. Activation of p53 and interaction with MDM2 by p19ARF and
smARF. (A) NIH3T3 cells were transfected with vectors encoding
GFP, GFP-p19ARF, and GFP-smARF. Cells were harvested at 48 h
post-transfection and the lysates were subjected to immunoblotting
with antibodies speciﬁcally recognizing ARF, p53, p21, MDM2, and c-
tubulin. The position of each protein is shown at the left of each panel.
(B) NIH3T3 cells were transfected with vectors encoding HA-p19ARF
and HA-smARF, and harvested at 48 h post-transfection. p19ARF and
smARF proteins were immunoprecipitated from the cell lysates
100 lg) with antibody (2 lg) speciﬁcally recognizing HA-tag. The
immunoprecipitates were subjected to immunoblotting with antibodies
to C-terminus ARF and MDM2. The positions of HA-p19ARF, HA-
smARF, and MDM2 are shown at the left of the panels. Input: ca 30%
of cell lysate used for immunoprecipitation was loaded in the lane.
Fig. 3. Induction of cell death by GFP-tagged p19ARF and smARF.
NIH3T3 cells were transfected with vectors encoding GFP, GFP-
p19ARF, and GFP-smARF. Cells were harvested at 48 h post-trans-
fection and analyzed for cell death by FACS. Similar results were
obtained by the dye exclusion assay and when we used HA-tagged
constructs. In all cases, the diﬀerence is signiﬁcant (P < 0.005).
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antibody (NRS). The precipitates were separated on SDS–
PAGE gels and analyzed by Western blotting using antibodies
to the C-terminus of ARF and MDM2. As expected, MDM2
was found in an anti-HA immunoprecipitate of the lysate from
cells transfected with HA-tagged full-length ARF (HA-
p19ARF), while little MDM2 was detected in an anti-HA
immunoprecipitate from the HA-smARF-transfected cells
(Fig. 4B). The level of MDM2 was slightly lower in smARF
transfectants but the quantitative analysis showed that more
than 50% of the MDM2 protein bound to p19ARF, whereas
less than 5% of MDM2 was found to be in a complex with
smARF. Thus, as previously reported [14], smARF showed a
much lower aﬃnity for interaction with MDM2 in vivo.4. Discussion
In the present study, we investigated the intracellular actions
of smARF, which was previously reported to be located in the
mitochondria and induce cell death by autophagy [14]. To our
Y. Ueda et al. / FEBS Letters 582 (2008) 1459–1464 1463surprise, we detected the GFP-signal in the nucleus (largely in
the nucleoplasm) of the mouse ﬁbroblasts transfected with the
vector that allows expression of the GFP-tagged smARF pro-
tein. The signal seems to reﬂect that of the GFP-smARF fu-
sion protein because we did not detect any degradation
intermediates in the Western blot analysis using two diﬀerent
antibodies. This does not seem to be a cell type- or species-spe-
ciﬁc phenomenon because we found the nuclear GFP-smARF
in human HEK293T and HeLa cells as well.
It is possible that the GFP-tagging aﬀects the subcellular
localization of smARF because the GFP (ca 27 kDa) is signif-
icantly larger than smARF itself (ca 14 kDa), but cell frac-
tionation experiments revealed that smARF with a much
smaller tag such as an HA-tag was also present in the nu-
cleus. smARF was found in the mitochondria by immunoﬂu-
orescent staining [14]. However, it is highly probable that
smARF forms a complex with other molecules in the nucleus
and considering the small size of the smARF protein, the pos-
sibility cannot be excluded that the epitope in smARF is
masked by interaction with other molecules. In the cell frac-
tionation experiment, the nuclear fraction was highly contam-
inated with unlysed cells and it was almost impossible to tell
whether smARF is in the nucleus or not. To clarify this point,
we modiﬁed the fractionation protocol to eliminate the unly-
sed cells and found smARF (both GFP-smARF and HA-
smARF) in the nucleus. Thus, we conclude that smARF
can be transported into the nucleus. Consistent with our re-
sults, previous reports analyzing ARF function with deletion
mutants showed that the N-terminus ARF mutants, especially
the one lacking the ﬁrst 62 amino acids, were excluded
from the nucleolus, but still in the nucleoplasm and cyto-
plasm [20–22].
If smARF is located in the nucleus, what is its physiological
function? Because smARF lacks the domain mainly required
for interaction with MDM2, it is unlikely that smARF regu-
lates the activity of this ubiquitin ligase. However, given that
smARF is still capable of inducing the expression of p53,
although much less so than full-length p19ARF, smARF may
still be able to bind to MDM2 with a lower aﬃnity using an
additional MDM2 binding motif, which was originally found
in human p14ARF[23], or, alternatively, may interact with
and regulate other ubiquitin ligases for p53 such as ARF-
BP1 [13], Pirh2 [24], and COP1 [25]. Other possibility is that
smARF may functionally interact with nucleophosmin
(NPM) [9–11] and modulate its associated functions to control
cell proliferation and survival. Further studies will be required
to clarify these possibilities. Another issue is that if smARF
functions both in the mitochondria and in the nucleus, it is
feasible that smARF shuttles between the nucleus and the
cytoplasm (mitochondria) and GFP-tagging interferes with
the nuclear export of smARF. Because p53 is reported to be
exported from the nucleus before degradation [26] or
even transported into the mitochondria [27] to induce apopto-
sis or autophagy, this possibility should also be tested in the
future.
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